{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:30:13Z","timestamp":1787142613414,"version":"build-2736575974"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJZD-M202501106"],"award-info":[{"award-number":["KJZD-M202501106"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","award":["2025KC038"],"award-info":[{"award-number":["2025KC038"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010211","name":"Education Department of Jilin Province","doi-asserted-by":"publisher","award":["JJKH20262168BS"],"award-info":[{"award-number":["JJKH20262168BS"]}],"id":[{"id":"10.13039\/501100010211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572406"],"award-info":[{"award-number":["82572406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biotechadv.2026.108980","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:13:05Z","timestamp":1783627985000},"page":"108980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rewiring cellular immunotherapy: From CAR evolution to circuit innovations across diseases"],"prefix":"10.1016","volume":"92","author":[{"given":"Jiayi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaogang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.trecan.2026.01.007","article-title":"In vivo CAR T cell engineering: design principles and open questions","volume":"12","author":"Aalipour","year":"2026","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","article-title":"Small-molecule control of CAR T cells","volume":"9","author":"Adams","year":"2025","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0020","article-title":"CAR-T cells: current status, challenges, and future prospects","volume":"7","author":"Adly","year":"2026","journal-title":"MedComm (2020)"},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0035","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3390\/cimb46040183","article-title":"Augmenting the antitumor efficacy of natural killer cells via SynNotch receptor engineering for targeted IL-12 secretion","volume":"46","author":"Ahmadnia","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0045","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0050","article-title":"Bioengineering the metabolic network of CAR T cells with GLP-1 and urolithin A increases persistence and long-term anti-tumor activity","volume":"6","author":"Akhtar","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41568-022-00505-x","article-title":"Rethinking cancer targeting strategies in the era of smart cell therapeutics","volume":"22","author":"Allen","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"6625","key":"10.1016\/j.biotechadv.2026.108980_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/br.2020.1355","article-title":"Novel genetic therapeutic approaches for modulating the severity of \u03b2-thalassemia (review)","volume":"13","author":"Amjad","year":"2020","journal-title":"Biomed. Rep."},{"issue":"7814","key":"10.1016\/j.biotechadv.2026.108980_bb0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0080","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0085","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-025-68272-5","article-title":"AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108980_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41569-019-0200-7","article-title":"Molecular mechanisms of arrhythmogenic cardiomyopathy","volume":"16","author":"Austin","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"7971","key":"10.1016\/j.biotechadv.2026.108980_bb0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"47","key":"10.1016\/j.biotechadv.2026.108980_bb0100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2249.2010.04197.x","article-title":"Immunotherapy prospects for acute myeloid leukaemia","volume":"161","author":"Barrett","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007426","article-title":"HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity","volume":"11","author":"Bassan","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0115","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"issue":"10297","key":"10.1016\/j.biotechadv.2026.108980_bb0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41582-023-00839-6","article-title":"Implications of immunometabolism for smouldering MS pathology and therapy","volume":"19","author":"Bittner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0150","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0155","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nmeth.2926","article-title":"Principles of genetic circuit design","volume":"11","author":"Brophy","year":"2014","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7925","key":"10.1016\/j.biotechadv.2026.108980_bb0165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41590-023-01708-6","article-title":"Epigenetic checkpoints regulate the fate and function of CAR-T cells","volume":"25","author":"Casucci","year":"2024","journal-title":"Nat. Immunol."},{"issue":"7749","key":"10.1016\/j.biotechadv.2026.108980_bb0180","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"656","key":"10.1016\/j.biotechadv.2026.108980_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0190","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.274","article-title":"Recurrence of depressive disorders after interferon-induced depression","volume":"7","author":"Chiu","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0200","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"issue":"591","key":"10.1016\/j.biotechadv.2026.108980_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"19","key":"10.1016\/j.biotechadv.2026.108980_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308377","article-title":"Enhancing CAR macrophage efferocytosis via surface engineered lipid nanoparticles targeting LXR signaling","volume":"36","author":"Chuang","year":"2024","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0215","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0220","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2023.05.003","article-title":"Evaluation of diversity indices to estimate clonal dominance in gene therapy studies","volume":"29","author":"Corre","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbi.2021.02.009","article-title":"M1\/M2 polarization in major depressive disorder: disentangling state from trait effects in an individualized cell-culture-based approach","volume":"94","author":"Cosma","year":"2021","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05627-4","article-title":"Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells","volume":"22","author":"Court","year":"2024","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108980_bb0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic cancer: a review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0250","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-1246","article-title":"Enhancing proteasome activity in T cells alleviates exhaustion and improves antitumor immunity","author":"de Blas","year":"2026","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0255","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.biotechadv.2026.108980_bb0260","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0265","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41587-020-0520-5","article-title":"Cancer-eating immune cells kitted out with CARs","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41378-019-0112-z","article-title":"On-chip multiplexed single-cell patterning and controllable intracellular delivery","volume":"6","author":"Dong","year":"2020","journal-title":"Microsyst. Nanoeng."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"issue":"7643","key":"10.1016\/j.biotechadv.2026.108980_bb0280","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"215","key":"10.1016\/j.biotechadv.2026.108980_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114145","article-title":"Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits","volume":"43","author":"Frankel","year":"2024","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0300","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1688995","article-title":"Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy","volume":"16","author":"Frlic","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0310","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ymthe.2024.02.022","article-title":"Inhibitory CARs fail to protect from immediate T cell cytotoxicity","volume":"32","author":"Funk","year":"2024","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0315","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40265-022-01702-6","article-title":"Pharmacotherapeutic treatment of glioblastoma: where are we to date?","volume":"82","author":"Gatto","year":"2022","journal-title":"Drugs"},{"issue":"30","key":"10.1016\/j.biotechadv.2026.108980_bb0320","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104758118","article-title":"Dynamic chromatin regulatory landscape of human CAR T cell exhaustion","volume":"118","author":"Gennert","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0325","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1525-0016(03)00099-6","article-title":"Gene transfer into genomes of human cells by the sleeping beauty transposon system","volume":"8","author":"Geurts","year":"2003","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0330","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2741\/4703","article-title":"GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer","volume":"23","author":"Golubovskaya","year":"2018","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"25","key":"10.1016\/j.biotechadv.2026.108980_bb0335","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-025-02856-w","article-title":"Integrated epigenetic and genetic programming of primary human T cells","author":"Goudy","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0345","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0350","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0355","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","article-title":"Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening","volume":"316","author":"Guimaraes","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0360","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0365","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202300915","article-title":"A nano-electroporation-DNA tensioner platform enhances intracellular delivery and mechanical analysis toward rapid drug assessment","volume":"8","author":"Hang","year":"2024","journal-title":"Small Methods"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0380","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.biotechadv.2026.108980_bb0385","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0390","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"6534","key":"10.1016\/j.biotechadv.2026.108980_bb0395","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0400","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio.2529","article-title":"Human antibody-based chemically induced dimerizers for cell therapeutic applications","volume":"14","author":"Hill","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0405","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-026-02085-1","article-title":"Epigenetic editing to advance CAR T cell therapy","volume":"18","author":"Horvathova","year":"2026","journal-title":"Clin. Epigenetics"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0415","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0420","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.mt.6300404","article-title":"Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies","volume":"16","author":"Huang","year":"2008","journal-title":"Mol. Ther."},{"issue":"17","key":"10.1016\/j.biotechadv.2026.108980_bb0425","article-title":"BiTE-secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"15","key":"10.1016\/j.biotechadv.2026.108980_bb0430","article-title":"Microfluidic and nanofluidic intracellular delivery","volume":"8","author":"Hur","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0435","article-title":"Dynamic estimation of metabolic state during CAR T cell production","volume":"6","author":"Jagannathan","year":"2026","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0445","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0455","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.2147\/OTT.S245169","article-title":"Highly efficient targeting of EGFR-expressing tumor cells with UniCAR T cells via target modules based on Cetuximab\u00ae","volume":"13","author":"Jureczek","year":"2020","journal-title":"Onco. Targets Ther."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0460","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"95","key":"10.1016\/j.biotechadv.2026.108980_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"482","key":"10.1016\/j.biotechadv.2026.108980_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0475","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","article-title":"Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology","volume":"10","author":"Kembuan","year":"2024","journal-title":"Trends Cancer"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb0480","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"7764","key":"10.1016\/j.biotechadv.2026.108980_bb0485","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0490","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008555","article-title":"Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the sleeping beauty (SB) transposon system","volume":"12","author":"Khaniya","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0495","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2015.06.008","article-title":"The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression","volume":"64","author":"Kim","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0500","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0505","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.175015","article-title":"Chimeric antigen receptor macrophages target and resorb amyloid plaques","volume":"9","author":"Kim","year":"2024","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.biotechadv.2026.108980_bb0510","article-title":"Advancing allogeneic NK cell immunotherapy through microfluidic gene delivery","volume":"12","author":"Kim","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"3\u20134","key":"10.1016\/j.biotechadv.2026.108980_bb0515","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/hum.2019.194","article-title":"Differential transgene silencing of myeloid-specific promoters in the AAVS1 safe harbor locus of induced pluripotent stem cell-derived myeloid cells","volume":"31","author":"Klatt","year":"2020","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0520","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0525","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ccell.2023.09.015","article-title":"Co-op CARs for targeting acute myeloid leukemia","volume":"41","author":"Kondo","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12134","article-title":"Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells","volume":"7","author":"Korniotis","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0535","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0540","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0545","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0550","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0555","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0560","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0565","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"issue":"47","key":"10.1016\/j.biotechadv.2026.108980_bb0575","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2517786122","article-title":"Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0580","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0585","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0590","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb0595","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1016\/j.ymthe.2025.09.026","article-title":"Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0600","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.biotechadv.2026.108980_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202410975","article-title":"Enhancing chimeric antigen receptor T-cell generation via microfluidic mechanoporation and lipid nanoparticles","volume":"21","author":"Lim","year":"2025","journal-title":"Small"},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108980_bb0610","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.biotechadv.2026.108980_bb0615","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0620","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0625","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/md19110587","article-title":"\u03c9-3 DPA protected neurons from neuroinflammation by balancing microglia M1\/M2 polarizations through inhibiting NF-\u03baB\/MAPK p38 signaling and activating neuron-BDNF-PI3K\/AKT pathways","volume":"19","author":"Liu","year":"2021","journal-title":"Mar. Drugs"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108525","article-title":"Photoresponsive vaccine-like CAR-M system with high-efficiency central immune regulation for inflammation-related depression","volume":"34","author":"Liu","year":"2022","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0640","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0645","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02648-z","article-title":"CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies","volume":"25","author":"Liu","year":"2026","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0655","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41467-022-30216-8","article-title":"Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19","volume":"13","author":"Lu","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0660","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0665","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/2643-3230.BCD-23-0240","article-title":"Advancing CAR T-cell therapies with artificial intelligence: opportunities and challenges","volume":"6","author":"Luciani","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0670","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","article-title":"synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy","volume":"15","author":"Lupo","year":"2024","journal-title":"Nat. Commun."},{"issue":"7786","key":"10.1016\/j.biotechadv.2026.108980_bb0675","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652223","article-title":"CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0685","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0690","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"32","key":"10.1016\/j.biotechadv.2026.108980_bb0695","doi-asserted-by":"crossref","first-page":"51581","DOI":"10.18632\/oncotarget.9955","article-title":"Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved sleeping beauty transposon platform","volume":"7","author":"Magnani","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb0700","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0705","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41423-025-01290-x","article-title":"Harnessing nutrient scarcity for enhanced CAR-T-cell potency and safety in solid tumors","volume":"22","author":"Manchon","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0710","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0715","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark. Res."},{"issue":"19","key":"10.1016\/j.biotechadv.2026.108980_bb0720","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108980_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0730","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","article-title":"Metabolic engineering for optimized CAR-T cell therapy","volume":"6","author":"McPhedran","year":"2024","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0735","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0740","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","article-title":"Drugging the efferocytosis process: concepts and opportunities","volume":"21","author":"Mehrotra","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0745","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03839-24","article-title":"Engineering of CD8(+) T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses","volume":"16","author":"Meng","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0750","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"issue":"16","key":"10.1016\/j.biotechadv.2026.108980_bb0755","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0760","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0765","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0770","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0775","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1182\/blood-2023-191127","article-title":"Calibrated release IL15 bivalent CD33 and\/or FLT3 and NOT Emcn logic gated gene circuit CAR-NK cell therapy (SENTI-202) in venetoclax resistant patient derived xenograft acute myeloid leukemia models","volume":"142","author":"Muftuoglu","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0780","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0785","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0790","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0795","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108980_bb0800","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0805","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0810","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"6316","key":"10.1016\/j.biotechadv.2026.108980_bb0815","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0820","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s10020-025-01217-2","article-title":"Formononetin ameliorates depression-like behaviors through rebalancing microglia M1\/M2 polarization and inhibiting NLRP3 inflammasome: involvement of activating PPAR\u03b1-mediated autophagy","volume":"31","author":"Peng","year":"2025","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0825","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"issue":"620","key":"10.1016\/j.biotechadv.2026.108980_bb0830","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0835","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","article-title":"FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0840","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009960","article-title":"Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells","volume":"12","author":"Qi","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0845","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","article-title":"Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and bi-specific antitumor activity of T cells","volume":"27","author":"Qin","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0850","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","article-title":"Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects","volume":"18","author":"Qin","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0855","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6726","key":"10.1016\/j.biotechadv.2026.108980_bb0860","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4793","article-title":"Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs","volume":"386","author":"Reddy","year":"2024","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0865","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0870","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0875","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2015.15030363","article-title":"Post-stroke depression: a review","volume":"173","author":"Robinson","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102618","article-title":"Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing","volume":"36","author":"Roman Azcona","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biotechadv.2026.108980_bb0885","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-immunol-051116-052302","article-title":"Synthetic immunology: hacking immune cells to expand their therapeutic capabilities","volume":"35","author":"Roybal","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0890","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0895","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb0900","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"issue":"6576","key":"10.1016\/j.biotechadv.2026.108980_bb0905","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0910","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1038\/s41467-020-17970-3","article-title":"Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function","volume":"11","author":"Salzer","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0915","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0920","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"issue":"664","key":"10.1016\/j.biotechadv.2026.108980_bb0925","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"Seif","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.biotechadv.2026.108980_bb0930","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb0935","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-021-00511-y","article-title":"Ultrasensitive antigen density discrimination by synNotch","volume":"31","author":"Shukla","year":"2021","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb0940","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","article-title":"Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering","volume":"25","author":"Si","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0945","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb0950","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0955","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s42003-020-1045-7","article-title":"Successful delivery of large-size CRISPR\/Cas9 vectors in hard-to-transfect human cells using small plasmids","volume":"3","author":"S\u00f8ndergaard","year":"2020","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0960","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"16","key":"10.1016\/j.biotechadv.2026.108980_bb0965","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","article-title":"Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts","volume":"118","author":"Stewart","year":"2018","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb0970","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00262-022-03303-4","article-title":"Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement","volume":"72","author":"Suematsu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb0975","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"issue":"7952","key":"10.1016\/j.biotechadv.2026.108980_bb0980","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb0985","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"22","key":"10.1016\/j.biotechadv.2026.108980_bb0990","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb0995","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0006-3495(91)82054-9","article-title":"Electroporation of cell membranes","volume":"60","author":"Tsong","year":"1991","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1000","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaci.2023.11.005","article-title":"Hypogammaglobulinemia and immune dysregulation-not just 2 sides of a coin","volume":"153","author":"Uzel","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","article-title":"Fueling CARs: metabolic strategies to enhance CAR T-cell therapy","volume":"13","author":"Van der Vreken","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108980_bb1010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrc.2017.110","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108980_bb1015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/d41573-022-00024-2","article-title":"Repairing cardiac injury with transient CAR-T cells","volume":"21","author":"Villanueva","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb1020","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"issue":"26","key":"10.1016\/j.biotechadv.2026.108980_bb1025","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108980_bb1030","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7315218","article-title":"New strategies and in vivo monitoring methods for stem cell-based anticancer therapies","volume":"2018","author":"Wang","year":"2018","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1035","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb1040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108980_bb1045","first-page":"1937","article-title":"Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.biotechadv.2026.108980_bb1050","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.biotechadv.2026.108980_bb1055","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108980_bb1060","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/0008-5472.CAN-25-3748","article-title":"Optimizing in vivo CAR T-cell engineering for cancer immunotherapy","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02136","article-title":"Identification and characterization of post-activated B cells in systemic autoimmune diseases","volume":"10","author":"Wei\u00dfenberg","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable smart CAR-T design: a new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","volume":"640","author":"Wen","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"issue":"6258","key":"10.1016\/j.biotechadv.2026.108980_bb1080","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108980_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113779","article-title":"Sequentially conquering transfection obstacles of primary human T cells via non-classical lipid nanoparticles delivering reformative transposon system","volume":"383","author":"Wu","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13036-025-00499-8","article-title":"Termination sequence between an inducible promoter and ubiquitous chromatin opening element (UCOE) reduces gene expression leakage and silencing","volume":"19","author":"Yanagi","year":"2025","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.imlet.2019.06.002","article-title":"The making and function of CAR cells","volume":"212","author":"Zabel","year":"2019","journal-title":"Immunol. Lett."},{"issue":"26","key":"10.1016\/j.biotechadv.2026.108980_bb1105","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1911154117","article-title":"A conformation-specific ON-switch for controlling CAR T cells with an orally available drug","volume":"117","author":"Zajc","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108980_bb1110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2024.2371034","article-title":"Small molecule-regulated switches to provide functional control of CAR T cells within the patient","volume":"24","author":"Zajc","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108980_bb1125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cmet.2018.12.004","article-title":"Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair","volume":"29","author":"Zhang","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1130","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1924379","article-title":"CAR-T cell therapy in cancer: tribulations and road ahead","volume":"2020","author":"Zhang","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"32","key":"10.1016\/j.biotechadv.2026.108980_bb1135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba9628","article-title":"Detection and isolation of free cancer cells from ascites and peritoneal lavages using optically induced electrokinetics (OEK)","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"issue":"7926","key":"10.1016\/j.biotechadv.2026.108980_bb1140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108980_bb1145","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jconrel.2024.09.037","article-title":"New avenues for cancer immunotherapy: cell-mediated drug delivery systems","volume":"375","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb1150","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108980_bb1155","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","article-title":"Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances","volume":"368","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1160","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb1165","article-title":"Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108980_bb1170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12951-021-01148-0","article-title":"Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19","volume":"19","author":"Zhu","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108980_bb1175","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1021\/acsnano.4c01597","article-title":"Engineering a programmed death-ligand 1-targeting monobody via directed evolution for SynNotch-gated cell therapy","volume":"18","author":"Zhu","year":"2024","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108980_bb1180","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity","volume":"29","author":"Zou","year":"2021","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108980_bb1185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00005-018-0504-z","article-title":"Application of genome editing techniques in immunology","volume":"66","author":"Zych","year":"2018","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:47:37Z","timestamp":1787140057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975026001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":237,"alternative-id":["S0734975026001862"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108980","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewiring cellular immunotherapy: From CAR evolution to circuit innovations across diseases","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108980"}}